Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20127201 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394017 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394307 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394118 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394018 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394305 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394304 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394306 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL21394371 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL20127202 | 1.00 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11239425-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2022-02-01 | — | — | US | disclosed |
| US-10745362-B2 | Heterocyclic compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-18 | — | — | US | disclosed |
| US-20190296243-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| US-20180127385-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM LTD. (KR) | 2018-05-10 | — | — | US | disclosed |
| US-20180127385-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM LTD. (KR) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745362-B2 | Heterocyclic compound and organic light emitting device comprising same | CRY1, CRY2, PER2 | MAPT 1073/4885SMN1; SMN2 4089/4885KDM4E 2502/4885 |
| US-20180127385-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CRY2, PER2 | MAPT 1073/4885SMN1; SMN2 4089/4885KDM4E 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.